The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

6 Aug 2012 12:21

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer Silence Therapeuticsof existing shares to which voting rights are PLCattached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the ORA (Guernsey) Limitednotification obligation:iii 4. Full name of shareholder(s) (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 2 August 2012reached: v 6. Date on which issuer notified: 6 August 2012 7. Threshold(s) that is/are crossed or 22%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type of Situation previous Resulting situation after the triggering transactionshares to the triggering transaction if possible Number Number Number Number of voting % of voting using of of of shares rights rights x the ISIN CODE Shares Voting Rights Direct Direct xi Indirect Direct Indirect xii GB0008433350 Less than Less than 330,000,000 330,000,000 22.51% 3% 3% B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of voting instrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise Expiration Exercise/ Number of voting rights % of voting financial price date xvii Conversion instrument refers to rights xix, xx instrument period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 330,000,000 22.51%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: Chris Hill 15. Contact telephone number: 01481 738724

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
23rd Jul 20205:02 pmRNSResults of EGM
22nd Jul 20204:29 pmRNSHolding(s) in Company
22nd Jul 20204:24 pmRNSHolding(s) in Company
21st Jul 20207:00 amRNSSilence Therapeutics to Participate in Conferences
16th Jul 20207:00 amRNSMallinckrodt Exercise of Options
2nd Jul 202010:50 amRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCircular and notice of general meeting
30th Jun 202012:39 pmRNSHolding(s) in Company
29th Jun 20204:55 pmRNSHolding(s) in Company
23rd Jun 20207:00 amRNSBusiness Update
23rd Jun 20207:00 amRNSSubmission of Registration Statement to the US SEC
10th Jun 20205:58 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSResults of AGM
5th Jun 20204:33 pmRNSHolding(s) in Company
1st Jun 20204:19 pmRNSAdditional Listing
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20209:37 amRNSPDMR Shareholding
21st May 20204:28 pmRNSGrant of Share Options
20th May 20207:00 amRNSNASDAQ Intention to List
20th May 20207:00 amRNSBroker Appointment
20th May 20207:00 amRNSCompany Update
14th May 20207:00 amRNSParticipation at RBC Virtual Healthcare Conference
12th May 20204:12 pmRNSHolding(s) in Company
12th May 20209:30 amRNSPDMR Dealing
7th May 20207:00 amRNSNotice of AGM
20th Apr 20203:28 pmRNSAdditional listing – correction
20th Apr 20207:00 amRNSPDMR Dealing and Additional Listing
17th Apr 20209:34 amEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
16th Apr 20207:00 amRNSSilence Therapeutics publication of Annual Report
14th Apr 20207:00 amRNSFinal results year ended 31 December 2019
9th Apr 20207:00 amRNSSilence Announces COVID-19 Partnership
2nd Apr 20207:00 amRNSPresentation at Conference and Notice of Results
1st Apr 20204:12 pmRNSAdditional Listing
31st Mar 202011:51 amRNSHolding(s) in Company
30th Mar 20203:00 pmRNSHolding(s) in Company
25th Mar 20202:56 pmEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
25th Mar 20207:01 amRNSR&D Update
25th Mar 20207:00 amRNSCollaboration with AstraZeneca
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Mar 202012:07 pmRNSSecond Price Monitoring Extn
17th Mar 202012:02 pmRNSPrice Monitoring Extension
13th Mar 202012:07 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20201:23 pmRNSHolding(s) in Company
2nd Mar 202012:24 pmRNSHolding(s) in Company
19th Feb 20209:14 amRNSHolding(s) in Company
18th Feb 20207:03 amRNSSilence to Present at Cowen Health Care Conference
17th Feb 202010:00 amRNSSilence Launches Scientific Advisory Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.